title: Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma.
abstract: OBJECTIVE
  To investigate the prognostic factors after resection for hepatitis B virus (HBV)-associated intrahepatic cholangiocarcinoma (ICC) and to assess the impact of different extents of lymphadenectomy on patient survival.
  
  
  METHODS
  A total of 85 patients with HBV-associated ICC who underwent curative resection from January 2005 to December 2006 were analyzed. The patients were classified into groups according to the extent of lymphadenectomy (no lymph node dissection, sampling lymph node dissection and regional lymph node dissection). Clinicopathological characteristics and survival were reviewed retrospectively.
  
  
  RESULTS
  The cumulative 1-, 3-, and 5-year survival rates were found to be 60%, 18%, and 13%, respectively. Multivariate analysis revealed that liver cirrhosis (HR = 1.875, 95%CI: 1.197-3.278, P = 0.008) and multiple tumors (HR = 2.653, 95%CI: 1.562-4.508, P < 0.001) were independent prognostic factors for survival. Recurrence occurred in 70 patients. The 1-, 3-, and 5-year disease-free survival rates were 36%, 3% and 0%, respectively. Liver cirrhosis (HR = 1.919, P = 0.012), advanced TNM stage (stage III/IV) (HR = 2.027, P < 0.001), and vascular invasion (HR = 3.779, P = 0.02) were independent prognostic factors for disease-free survival. Patients with regional lymph node dissection demonstrated a similar survival rate to patients with sampling lymph node dissection. Lymphadenectomy did not significantly improve the survival rate of patients with negative lymph node status.
  
  
  CONCLUSIONS
  The extent of lymphadenectomy does not seem to have influence on the survival of patients with HBV-associated ICC, and routine lymph node dissection is not recommended, particularly for those without lymph node metastasis.
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Zhen-Feng
authors.initials: ZF
authors.lastname: Wu
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Wu
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Nan
authors.initials: N
authors.lastname: Zhu
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Zhe
authors.initials: Z
authors.lastname: Xu
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Wei-Su
authors.initials: WS
authors.lastname: Li
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Hai-Bin
authors.initials: HB
authors.lastname: Zhang
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Yang
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Xue-Quan
authors.initials: XQ
authors.lastname: Yao
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Fu-Kun
authors.initials: FK
authors.lastname: Liu
authors.affiliation: Zhen-Feng Wu, Xiao-Yu Wu, Zhe Xu, Wei-Su Li, Xue-Quan Yao, Fu-Kun Liu, Department of Surgical Oncology, Jiangsu Province Hospital of Traditional Chinese Medicine, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
authors.forename: Guang-Shun
authors.initials: GS
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000821:virology; D001653:Bile Ducts, Intrahepatic / Q000473:pathology / Q000601:surgery* / Q000821:virology; D016009:Chi-Square Distribution; D018281:Cholangiocarcinoma / Q000401:mortality / Q000556:secondary / Q000601:surgery* / Q000821:virology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects / Q000401:mortality; D006509:Hepatitis B / Q000150:complications* / Q000175:diagnosis / Q000401:mortality; D006801:Humans; D008197:Lymph Node Excision / Q000009:adverse effects / Q000401:mortality; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018579:Patient Selection; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
keywords: Hepatitis B virus; Intrahepatic cholangiocarcinoma; Lymph node dissection; Lymph node metastases; Postoperative survival